Evidence map›Paper›PMID 34206304›Full record

ReviewJournal of fungi (Basel, Switzerland)2021

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects.

Mousa A Alghuthaymi, Atef A Hassan, Anu Kalia, Rasha M H Sayed El Ahl, Ahmed A M El Hamaky, Patrik Oleksak, Kamil Kuca, Kamel A Abd-Elsalam

Open access · goldAbstract readReview
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Special Issue: Fungal Nanotechnology.Journal of fungi (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Mousa A AlghuthaymiBiology Department, Science and Humanities College, Shaqra University, Alquwayiyah 19245, Saudi Arabia.
Atef A HassanDepartment of Mycology, Animal Health Research Institute (AHRI), Agriculture Research Center (ARC), 12611 Giza, Egypt.
Anu KaliaElectron Microscopy and Nanoscience Laboratory, Department of Soil Science, College of Agriculture, Punjab Agricultural University, Ludhiana 141004, India.ORCID 0000-0001-8367-1923
Rasha M H Sayed El AhlDepartment of Mycology, Animal Health Research Institute (AHRI), Agriculture Research Center (ARC), 12611 Giza, Egypt.
Ahmed A M El HamakyDepartment of Mycology, Animal Health Research Institute (AHRI), Agriculture Research Center (ARC), 12611 Giza, Egypt.
Patrik OleksakDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech Republic.
Kamil KucaDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech Republic.ORCID 0000-0001-9664-1109
Kamel A Abd-ElsalamPlant Pathology Research Institute, Agricultural Research Center (ARC), 9-Gamaa St., 12619 Giza, Egypt.ORCID 0000-0002-4042-4022
Agricultural Genetic Engineering Research Institute · EGUniversity of Hradec Králové · CZAgricultural Research Center · EGPunjab Agricultural University · INShaqra University · SA

Funding

University of Hradec Kralove UHK VT2019-2021
6 · The paper itself

Abstract

The global recognition for the potential of nanoproducts and processes in human biomedicine has given impetus for the development of novel strategies for rapid, reliable, and proficient diagnosis, prevention, and control of animal diseases. Nanomaterials exhibit significant antifungal and antimycotoxin activities against mycosis and mycotoxicosis disorders in animals, as evidenced through reports published over the recent decade and more. These nanoantifungals can be potentially utilized for the development of a variety of products of pharmaceutical and biomedical significance including the nano-scale vaccines, adjuvants, anticancer and gene therapy systems, farm disinfectants, animal husbandry, and nutritional products. This review will provide details on the therapeutic and preventative aspects of nanoantifungals against diverse fungal and mycotoxin-related diseases in animals. The predominant mechanisms of action of these nanoantifungals and their potential as antifungal and cytotoxicity-causing agents will also be illustrated. Also, the other theragnostic applications of nanoantifungals in veterinary medicine will be identified.

Indexed as

mycotoxin degradationnanoantifungaltheragnosticveterinary

Identifiers

PMID34206304
PMCPMC8303737
OpenAlexW3175919313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.